University of California, Riverside   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Riverside CA United States (1954)

Organization Overview

First Clinical Trial
2005
NCT00977028
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Midland Research Group | Midland Research Group, Inc. | Riverside County Regional Medical Center | University of California Riverisde School of Medicine | University of California, Riverside | University of California Riverside at C.I. Trials, Inc.-Inland Empire | University of Californiia, Riverside

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 4)

Childhood-Onset Fluency Disorder (Phase 3)

Communication Disorders (Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Disease (Phase 3)

Hemorrhage (Phase 1)

HIV Infections (Phase 4)

Hypoglycemia (Phase 4)

Language Disorders (Phase 3)

Schizophrenia (Phase 2)

Speech Disorders (Phase 3)

Stuttering (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 14